Product Information
ATORVASTATIN 80 MG TABLET is a generic product labeled by Quallent Pharmaceuticals Health LLC, priced at $0.0693 per EA under NDC 82009017910. Its NADAC has been published 48 times since Nov 5, 2025.
FDA first approved this application on Sep 12, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the ATORVASTATIN CALCIUM market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
80 mg/1
Manufacturer
Quallent Pharmaceuticals Health LLCNDC
82009017910
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ATORVASTATIN CALCIUM TRIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA214344FDA Approved
9/12/2023
TE Code
AB
On Market Since
8/1/2025
Pharmacological Classes
Price Statistics
The NADAC for ATORVASTATIN 80 MG TABLET has been published 48 times since Nov 5, 2025, and over the history we have for it it has declined 2.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0693 per EA |
|---|---|
| All-time high | $0.0726 (Jan 14, 2026) |
| All-time low | $0.0692 (Jul 22, 2026) |
| 52-week high | $0.0726 |
| 52-week low | $0.0692 |
| Median price | $0.0710 |
| Average price | $0.0709 |
| Largest weekly change | +2.0% (Dec 17, 2025) |
| Weeks tracked | 48 |
| Tracking since | Nov 5, 2025 |
Generic Alternatives
The matcher finds 10 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Quallent Pharmaceuticals Health LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ATORVASTATIN CALCIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
HMG-CoA Reductase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATORVASTATIN 80 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATORVASTATIN 80 MG TABLET, manufactured by Quallent Pharmaceuticals Health LLC, is $0.0693 per EA (NDC 82009017910), effective Sep 30, 2026.
How has the price of ATORVASTATIN 80 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATORVASTATIN 80 MG TABLET has declined 2.9%. It has been tracked across 48 weekly CMS publications since Nov 5, 2025.
What are the highest and lowest recorded NADAC prices for ATORVASTATIN 80 MG TABLET?
Since Nov 5, 2025, the NADAC for ATORVASTATIN 80 MG TABLET has ranged from a low of $0.0692 (Jul 22, 2026) to a high of $0.0726 (Jan 14, 2026), with a median of $0.0710 per EA.
Are there cheaper alternatives to ATORVASTATIN 80 MG TABLET?
Yes. 10 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ATORVASTATIN 80 MG TABLET, is $0.0635 per EA — about 8% below ATORVASTATIN 80 MG TABLET.
Who manufactures ATORVASTATIN 80 MG TABLET?
ATORVASTATIN 80 MG TABLET (NDC 82009017910) is labeled by Quallent Pharmaceuticals Health LLC, and CMS classifies it as a generic product.